EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Editorial: Traditional medicine inspired drug development against central nervous system (CNS) disorders

Sushil Kumar Chaudhary, Claudia Ntsapi-Combrink, Aliyu Muhammad, Chika Ifeanyi Chukwuma, Mostafa Alilou

Frontiers in Pharmacology · 16.11.2026 · 17

DOI: 10.3389/fphar.2026.2027530 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 16.11.2026. Verfasst von Sushil Kumar Chaudhary und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

neurotransmitter regulation. Importantly for CNS drug development, ATL-III has demonstrated bloodbrain barrier penetration, although the authors identify pharmacological and toxicological characterisation, bioavailability, brain retention, and clinical evaluation as necessary next steps. Zhang et al. (2026) similarly examine Astragaloside IV as a potential neuroprotective agent for stroke, highlighting anti-inflammatory, antioxidative, and other pharmacological effectsdrawing on in vitro and in vivo studies to highlight anti-inflammatory, antioxidative, and other pharmacological effects and its potential role as an adjunctive therapy.The multi-target nature of natural products and botanical medicines is particularly evident in the contributions concerning Alzheimer's disease (AD). Wang et al. (2026) systematically analyse 28 preclinical studies of Kai-xin-san, reporting improvements in behavioural measures and changes involving Aβ and tau pathology, inflammation, oxidative stress and cholinergic function. The authors nevertheless caution that high risk of bias may result in overestimation of these effects and call for higher-quality preclinical evidence before clinical efficacy is considered. Li et al. (2026) examine botanical metabolites targeting programmed cell death pathways including apoptosis, ferroptosis, autophagy and pyroptosis, while also identifying important limitations including pan-assay interference compounds, inadequate representation of sporadic AD in existing models, bioavailability and brain targeting. Ntsapi et al. (2026) focus specifically on the potential relationship between cannabinoids, autophagy and neuronal survival, proposing multi-cannabinoid approaches as an area requiring further experimental investigation. Xu et al. (2025) provide an important reminder that therapeutic activity cannot be separated from safety. Using metabolomic, histological, and molecular approaches, the authors report that Huang-Lian-Jie-Du Decoction reduced Aβ deposition, inflammation, and neuronal damage and preserved bloodbrain barrier integrity in an AD rat model. However, administration to normal rats was associated with inflammation, impaired neuronal function, compromised blood-brain barrier integrity, and organ damage. These differential effects demonstrate why biological context and toxicity assessment must form part of the development pathway rather than being considered only after efficacy has been established. Experimental models provide another critical bridge between candidate identification and translation. Shao et al. (2026) highlight zebrafish as a platform for investigating neuroprotective traditional medicines, particularly for high-throughput screening, real-time imaging, and rapid safety assessment. At the same time, they identify limitations in neuroanatomy, drug metabolism, and the predominance of acute disease models, supporting the need for model standardisation and cross-species validation. Ranjbari et al. (2026), using a rat model, report anxiolytic-and antidepressant-like effects of astaxanthin associated with GABAergic, cholinergic and opioid pathways as well as antioxidant and anti-inflammatory mechanisms. Wang et al. (2026) similarly synthesise preclinical evidence for Sinisan in depression models, reporting changes in behavioural outcomes, monoamine neurotransmitters, hypothalamic-pituitary-adrenal axis hormones and inflammatory markers, while cautioning that heterogeneity, risk of bias and inadequate phytochemical characterisation limit interpretation.Stroke-related contributions illustrate particularly well how evidence can progress from mechanistic investigation towards clinical evaluation. Lee et al. (2026) report that Chunghyul-dan reduced infarct volume and provided multi-level neurovascular protection in experimental ischemia, includingin preclinical models of ischemia, including effects on collateral perfusion, vascular adaptation, neuroinflammation and endothelial barrier integrity. Huang et al. (2025) integrate clinical and preclinical evidence concerning traditional Chinese medicine interventions for post-stroke cerebral edema, identifying potential effects involving ion homeostasis, aquaporins, neuroinflammation, oxidative stress, apoptosis and blood-brain barrier protection. Ren et al. (2025) extend this to comparative clinical evidence through a network meta-analysis of 70 randomised controlled trials involving 6,227 patients with acute ischemic stroke. Although several Fuzheng traditional Chinese medicine injections combined with conventional treatment showed favourable outcomes, the authors appropriately caution that methodological limitations constrain the certainty of these findings. Clinical evidence is also represented in migraine and amyotrophic lateral sclerosis (ALS). Zhang et al. (2026) synthesise 57 randomised controlled trials involving 6,005 participants and identify differences in the relative performance of Chinese botanical drug decoctions for migraine, while emphasising variability in study quality and the indirect nature of treatment comparisons. Shen et al. (2026) examine 35 randomised controlled trials of traditional Chinese medicine therapies for ALS. Although some interventions achieved favourable probability rankings, no significant differences in functional status were identified between traditional Chinese medicine therapies, integrated conventional treatment, Riluzole alone, and Riluzole with placebo. This distinction between treatment ranking and demonstrated superiority is important and illustrates the need for caution when translating comparative evidence into therapeutic claims. Even where clinical data exist, favourable rankings do not constitute demonstrated clinical efficacy. Deng et al. (2026) further broaden the scope of the Topic through their examination of natural products and traditional Chinese medicine formulations for ADHD. Their synthesis identifies potential mechanisms involving catecholamine neurotransmission, neurodevelopment and synaptic plasticity, neuroinflammation and the gut-brain axis, while highlighting reliance on individual animal models and insufficient pharmacokinetic and translational evidence. These limitations are not unique to ADHD but reflect wider challenges across the field. Indeed, the quality Indeed, the quality of the evidence base itself must be considered part of drug development. Wang et al. (2026) meta-epidemiological analysis provides an important critical perspective: among 79 systematic reviews and meta-analyses of natural product extracts for ischemic stroke, 86.1% were rated as critically low in methodological quality, and substantial publication redundancy was identified. Their findings show that increasing the volume of evidence does not necessarily strengthen confidence if methodological weaknesses are repeatedly reproduced. Taken together, the contributions suggest a useful framework for the next phase of traditional-medicine-inspired CNS drug development. Traditional knowledge and natural-product diversity provide candidate compounds and formulations, but these candidates require progressive filtering through phytochemical characterisation, mechanistic investigation, appropriate disease models, pharmacokinetics, toxicity and safety assessment, blood-brain barrier and brain-targeting considerations, and ultimately well-designed clinical studies.Traditional knowledge and naturalproduct diversity provide candidates, but each requires progressive filtering through phytochemical characterisation, mechanistic and model-based investigation, pharmacokinetic and safety assessment, and ultimately well-designed clinical studies. Computational approaches, including molecular docking, network pharmacology and machine learning, may increasingly assist in integrating these layers of evidence and prioritising candidates, but prediction cannot substitute for experimental validation.Across the 16 publications, the evidence converges around five interconnected research areas: stroke and neurovascular protection, Alzheimer's disease and neurodegeneration, neuropsychiatric and neurodevelopmental disorders, mechanisms of neuroprotection, and clinical and evidence synthesis.clinical evidence synthesis (Figure 1). The stroke studies examine Astragaloside IV, Fuzheng injections, Chunghyul-dan, natural-product extracts and traditional Chinese medicine for post-stroke cerebral edema, with recurring mechanisms involving neuroinflammation, oxidative stress, vascular protection and blood-brain barrier integrity. Alzheimer's-focused studies investigate Huang-Lian-Jie-Du Decoction, Kai-xin-san, cannabinoids and botanical metabolites, converging on Aβ and tau pathology, autophagy, programmed cell death, inflammation, oxidative stress and neuronal survival.The neuropsychiatric and neurodevelopmental studies extend these shared mechanisms to ADHD, depression and anxiety through neurotransmitter regulation, synaptic plasticity, the gut-brain axis, HPA-axis regulation and inflammatory pathways. Across these disease-specific areas, the papers repeatedly describe multi-target neuroprotective effects rather than isolated mechanisms, but they also converge on four major barriers to translation: safety and toxicity, bioavailability and brain targeting, the validity and translational relevance of experimental models, and the quality of the evidence supporting efficacy. These concerns become particularly important in the systematic reviews and network meta-analyses, where promising results are frequently qualified by risk of bias, methodological limitations, heterogeneity or uncertainty in comparative evidence; notably, the methodological analysis of ischemic-stroke reviews found 86.1% to be of critically low methodological quality. Overall, the network shows that although the 16 publications investigate different medicines and CNS disorders, they collectively describe the same translational problem: moving from multi-target biological and preclinical promise towards compounds or formulations that are sufficiently characterised, safe, brainaccessible, experimentally reproducible and supported by rigorous clinical evidence to justify development as CNS therapeutics (Figure 1).Recurring mechanisms include neuroinflammation, oxidative stress, blood-brain barrier integrity, programmed cell death and autophagy in stroke and Alzheimer's disease, and neurotransmitter regulation, synaptic plasticity, HPA-axis regulation and the gut-brain axis in neuropsychiatric and neurodevelopmental disorders. Most of this evidence is preclinical, whereas the clinical evidence derives from meta-analyses of randomised controlled trials in stroke, migraine and ALS. Across all areas, the contributions converge on four barriers to translation: safety and toxicity, bioavailability and brain targeting, the validity and translational relevance of experimental models, and the quality of the evidence supporting efficacy. The significance of this research topic therefore lies not only in demonstrating therapeutic potential. It also identifies where that potential can be lost between discovery and translation. Traditional medicine offers a rich starting point for CNS drug development, but historical use, mechanistic plausibility, preclinical efficacy and even favourable comparative rankings represent different levels of evidence.but historical use, mechanistic plausibility, preclinical efficacy and favourable comparative clinical rankings represent successively higher yet distinct levels of evidence, and none is equivalent to demonstrated clinical efficacy, which requires rigorous, adequately powered randomised trials. Progress will depend on connecting these levels through rigorous, reproducible and transparent translational pipelines. The future opportunity is not simply to identify more promising natural products, but to become better at determining which candidates are sufficiently characterised, safe, biologically plausible and evidence-supported to progress towards clinically meaningful CNS therapies.but to determine which candidates merit progression towards clinically meaningful CNS therapies.

Zitieren

APA

Chaudhary, S. K., Ntsapi-Combrink, C., Muhammad, A., Chukwuma, C. I., & Alilou, M. (2026). Editorial: Traditional medicine inspired drug development against central nervous system (CNS) disorders. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.2027530

Vancouver

Chaudhary SK, Ntsapi-Combrink C, Muhammad A, Chukwuma CI, Alilou M. Editorial: Traditional medicine inspired drug development against central nervous system (CNS) disorders. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.2027530

BibTeX
@article{Chaudhary2026,
  author = {Chaudhary, Sushil Kumar and Ntsapi-Combrink, Claudia and Muhammad, Aliyu and Chukwuma, Chika Ifeanyi and Alilou, Mostafa},
  title = {Editorial: Traditional medicine inspired drug development against central nervous system (CNS) disorders},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.2027530}
}
Kostenlos starten →